Drug safety evaluation of adefovir in HBV infection

Bibliography

• Keeffe EB, Zeuzem S, Koff RS, Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7
   PubMed Web of Science ®Google Scholar
• Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;10:661-2
   Google Scholar
• Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49:S185-95
   Web of Science ®Google Scholar
• Hepsera prescribing information. Gilead Sciences, Inc.; 2002; p. 1-18
   Google Scholar
• Dando TM, Plosker GL. Adefovir dipivoxil a review of its use in chronic hepatitis B. Drugs 2003;63:2215-34
   PubMed Web of Science ®Google Scholar
• Knight W, Hayashi S, Benhamou Y, Dosing guidelines for adefovir in the treatment of chronic hepatitis B patients with renal or hepatic impairment. J Hepatol 2003;38:A308
   Google Scholar
• Shiffman ML, Pol S, Rostaing L, Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. J Clin Pharmacol 2010; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ono-Nita SK, Kato N, Shiratori Y, Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999;102:1635-40
   Google Scholar
• Xiong X, Flores C, Yang H, Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998;28:1669-73
   PubMed Web of Science ®Google Scholar
• Fisher EJ, Chaloner K, Cohn DL, Community programs for clinical research on AIDS: the safety and efficacy of adefovir dipivoxil in patients with adefovir dipivoxil and HIV disease: a randomized, placebo controlled trial. AIDS 2001;15:1695-700
   PubMed Web of Science ®Google Scholar
• Kahn J, Lagakos S, Wulfsohn M, Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999;282:2305-12
   PubMed Web of Science ®Google Scholar
• Jeffers L, Heathcote E, Wright T, A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection. Antiviral Res 1998;37:A197
   Google Scholar
• Marcellin P, Chang TT, Lim SG, Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Adefovir dipivoxil 438 study group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Thibault V, Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23
   PubMed Web of Science ®Google Scholar
• Perrillo R, Hann HW, Mutimer D, Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90
   PubMed Web of Science ®Google Scholar
• Peters MG, Hann Hw H, Martin P, Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101
   PubMed Web of Science ®Google Scholar
• Schiff ER, Lai CL, Hadziyannis S, Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in preand post-liver transplantation patients. Hepatology 2003;38:1419-27
   PubMed Web of Science ®Google Scholar
• Schiff E, Lai CL, Hadziyannis S, Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007;13:349-60
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
   PubMed Web of Science ®Google Scholar
• Tanji N, Tanji K, Kambham N, Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001;32:734-40
   PubMed Web of Science ®Google Scholar
• Imaoka T, Kusuhara H, Adachi M, Functional involvement of multidrug resistance-associated protein 4 in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007;71:619-27
   PubMed Web of Science ®Google Scholar
• Cihlar T, Lin DC, Pritchard JB, The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999;56:570-80
   PubMed Web of Science ®Google Scholar
• Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 2001;299:567-74
   PubMed Web of Science ®Google Scholar
• Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005;45:804-17
   PubMed Web of Science ®Google Scholar
• Schuetz JD, Connelly MC, Sun D, MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5:1048-51
   PubMed Web of Science ®Google Scholar
• Wijnholds J, Mol CA, van Deemter L, Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000;97:7476-81
   PubMed Web of Science ®Google Scholar
• Vigano M, Lampertico P, Dongiovanni P, A drug transporter gene polymorphism predicts renal tubular toxicity in patients with chronic hepatitis B on long-term adefovir and lamivudine combination. J Hepatol 2010;52:S7
   Google Scholar
• Izzedine H, Hulot JS, Launay-Vacher V, Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004;66:1153-8
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8
   PubMed Web of Science ®Google Scholar
• Zeng M, Mao Y, Yao G, A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006;44:108-16
   PubMed Web of Science ®Google Scholar
• Ha NB, Ha NB, Garcia RT, Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727-34
   PubMed Web of Science ®Google Scholar
• Sung JJ, Lai JY, Zeuzem S, Lamivudine compared with lamivudine and adefovir for the treatment of HBeAg positive chronic hepatitis B. J Hepatol 2008;48:728-35
   PubMed Web of Science ®Google Scholar
• Hui CK, Zhang HY, Bowden S, 96 weeks combination of adefovir dipivoxil plus emtricitabine vs adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008;48:714-20
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Lutgehetmann M, Dandri M, Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84
   PubMed Web of Science ®Google Scholar
• Piccolo P, Lenci I, Demelia L, A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009;14:1165-74
   PubMed Web of Science ®Google Scholar
• Perrillo R, Schiff E, Yoshida E, Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Manenti E, Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine resistant hepatitis B patients. Gastroenterology 2007;133:1445-51
   PubMed Web of Science ®Google Scholar
• Rapti I, Dimou E, Mitsoula P, Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-13
   PubMed Web of Science ®Google Scholar
• Yatsuji H, Suzuki F, Sezaki H, Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008;48:923-31
   PubMed Web of Science ®Google Scholar
• Tamori A, Enomoto M, Kobayashi S, Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat 2010;17:123-9
   PubMed Web of Science ®Google Scholar
• Vigano M, Lampertico P, Iavarone M, High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B. Hepatology 2008;48:708A
   Google Scholar
• Lee JM, Park JY, Kim Do Y, Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010;15:235-41
   PubMed Web of Science ®Google Scholar
• Zoulim F, Parvaz P, Marcellin P, Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver Int 2009;29:420-6
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Raptopoulou-Gigi M, Cheinquer H, Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology 2009;50:505A
   Google Scholar
• Fontaine H, Vallet-Pichard A, Chaix ML, Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005;80:1086-92
   PubMed Web of Science ®Google Scholar
• de Silva HJ, Dassanayake AS, Manamperi A, Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc 2006;38:3118-20
   PubMed Web of Science ®Google Scholar
• Kamar N, Huart A, Tack I, Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. Clin Nephrol 2009;71:36-42
   PubMed Web of Science ®Google Scholar
• Tse KC, Yap DY, Tang CS, Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant 2010;24:207-12
   PubMed Web of Science ®Google Scholar
• Tillmann HL, Bock CT, Bleck JS, Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl 2003;9:191-6
   PubMed Web of Science ®Google Scholar
• Gornals JB, Casanovas T, Sabido M, Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection. Transplant Proc 2005;37:3957-9
   PubMed Web of Science ®Google Scholar
• Jonas MM, Kelly D, Pollack H, Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to < 18 years) with chronic hepatitis B. Hepatology 2008;47:1863-71
   PubMed Web of Science ®Google Scholar
• Izzedine H, Kheder-Elfekih R, Housset P, Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient. AIDS 2009;23:544-5
   PubMed Web of Science ®Google Scholar
• Jung YK, Yeon JE, Choi JH, Fanconi's syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient. Gut Liver 2010;4:389-93
   PubMed Web of Science ®Google Scholar
• Girgis CM, Wong T, Ngu MC, Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. J Clin Gastroenterol 2011;45:468-73
   PubMed Web of Science ®Google Scholar
• Vigano M, Lampertico P, Eller-Vainicher C, High prevalence of reduced bone mineral density in patients with chronic hepatitis B under nucleos(t)ides analogues treatment. Hepatology 2010;52:526A
   Google Scholar